Clinical Trial Update: Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation Phase 1/2 trial of QR-010 in adults with homozygous ΔF508 cystic fibrosis has completed. Results were posted in February 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• QR-010

Snippet

Sponsor: ProQR Therapeutics | Conditions: Cystic Fibrosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-02-06